HealthEquity, Inc. (NASDAQ:HQY) Shares Acquired by Citigroup Inc.

Citigroup Inc. raised its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 73.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,107 shares of the company's stock after acquiring an additional 43,084 shares during the period. Citigroup Inc. owned approximately 0.12% of HealthEquity worth $8,357,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Trust N.A. boosted its position in shares of HealthEquity by 4.8% during the 3rd quarter. Raymond James Trust N.A. now owns 2,905 shares of the company's stock worth $238,000 after purchasing an additional 132 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in HealthEquity by 1.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,061,807 shares of the company's stock worth $86,909,000 after purchasing an additional 14,532 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of HealthEquity by 7.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 484,782 shares of the company's stock worth $39,679,000 after buying an additional 33,523 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of HealthEquity in the third quarter valued at $4,157,000. Finally, Intech Investment Management LLC raised its holdings in shares of HealthEquity by 59.5% in the 3rd quarter. Intech Investment Management LLC now owns 21,064 shares of the company's stock valued at $1,724,000 after buying an additional 7,859 shares during the period. 99.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at HealthEquity

In other news, Director Robert W. Selander sold 8,250 shares of the company's stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares of the company's stock, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank Corvino sold 1,039 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the sale, the director now owns 3,784 shares of the company's stock, valued at $363,642.40. This trade represents a 21.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,536 shares of company stock valued at $884,517 in the last ninety days. Insiders own 2.20% of the company's stock.

HealthEquity Stock Down 0.9 %

NASDAQ HQY traded down $0.93 during trading on Friday, reaching $101.54. 452,817 shares of the company's stock were exchanged, compared to its average volume of 625,647. The company has a 50 day moving average price of $90.16 and a two-hundred day moving average price of $82.76. The stock has a market cap of $8.87 billion, a P/E ratio of 84.62, a price-to-earnings-growth ratio of 1.60 and a beta of 0.52. HealthEquity, Inc. has a 1 year low of $62.10 and a 1 year high of $105.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.16. The firm had revenue of $299.93 million during the quarter, compared to analysts' expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. On average, equities research analysts anticipate that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Barrington Research restated an "outperform" rating and issued a $105.00 price objective on shares of HealthEquity in a report on Friday, September 20th. BTIG Research upped their target price on shares of HealthEquity from $110.00 to $130.00 and gave the stock a "buy" rating in a research note on Thursday, November 14th. JMP Securities reissued a "market outperform" rating and issued a $105.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Bank of America upped their price objective on HealthEquity from $100.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, HealthEquity presently has an average rating of "Moderate Buy" and a consensus price target of $107.23.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.